Shopping Cart 0
Cart Subtotal
USD 0

Laurus Labs Ltd (LAURUSLABS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Laurus Labs Ltd (Laurus Labs) is a drug development company that manufactures active pharmaceutical ingredients. The company develops products through its business divisions such as laurus generics, ingredients and synthesis. It offers active pharmaceutical ingredients and intermediates for anti-retroviral and Hepatitis C. Laurus Labs also provides active pharmaceutical ingredients for oncology and other therapeutic areas. The company manufactures ingredients for use in nutraceutical, dietary supplements and cosmeceutical products. It also offers drug substance, analytical development and product development services. The company operates research and development, and drug substance manufacturing facilities in Hyderabad and Visakhapatnam. Laurus Labs is headquartered in Hyderabad, Telangana, India.

Laurus Labs Ltd (LAURUSLABS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Private Equity 10

Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10

Fidelity Growth Partners India Invests USD 40 Million In Aptuit Laurus 12

Licensing Agreements 13

Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13

MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15

Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16

Equity Offering 17

Laurus Labs Raises USD194 Million in IPO 17

Acquisition 18

Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18

Laurus Labs Ltd-Key Competitors 19

Laurus Labs Ltd-Key Employees 20

Laurus Labs Ltd-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Joint Venture 22

Recent Developments 23

Financial Announcements 23

Nov 09, 2017: Laurus Labs Records Healthy Performance, PAT Grows at 19% in H1 FY I8 23

May 18, 2017: Laurus Labs Reports Revenue Of INR19.3 Billion In Fiscal 2018 25

Feb 09, 2017: Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO 26

Corporate Communications 27

Mar 08, 2018: Laurus Labs: Resignation of Executive Director 27

Mar 08, 2018: Laurus Labs Appoints Dr. Venkata Lakshmana Rao Chunduru as Executive Director 28

Mar 28, 2017: Laurus Labs Announces Resignation of Director 29

Jan 02, 2017: Laurus Labs: Resignation of Director 30

Legal and Regulatory 31

Mar 01, 2018: Laurus Labs Completes USFDA Inspection Of Unit 2 With No Observations- Zero 483 31

Nov 14, 2017: laurus labs recieves the EIR for its unit 1 & 3 32

Sep 15, 2017: Laurus Labs Recivces the EIR from UFDA, and also Successfully Completes of the German Regulatory Authority for Unit-2 and WHO inspections for Unit-3 API Facilities 33

Aug 18, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection for Unit-1 and Unit-3 API Facilities 34

May 19, 2017: Laurus Labs Announces Successful Completion of U.S. FDA Inspection 35

Appendix 36

Methodology 36

About GlobalData 36

Contact Us 36

Disclaimer 36


List Of Figure

List of Figures

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Laurus Labs Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Laurus Labs Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Laurus Labs Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Warburg Pincus Acquires 32.29% Stake in Laurus Labs for USD90 Million 10

Fidelity Growth Partners India Invests USD 40 Million In Aptuit Laurus 12

Laurus Labs Enters into Licensing Agreement with Medicines Patent Pool 13

MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 14

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 15

Laurus Labs Amends Licensing Agreement with MPP and Gilead Sciences 16

Laurus Labs Raises USD194 Million in IPO 17

Laurus Labs Acquires 27% Stake in Sriam Labs for USD1.2 Million 18

Laurus Labs Ltd, Key Competitors 19

Laurus Labs Ltd, Key Employees 20

Laurus Labs Ltd, Other Locations 21

Laurus Labs Ltd, Subsidiaries 21

Laurus Labs Ltd, Joint Venture 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Laurus Labs Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.